Bellicum Pharmaceuticals
BLCM
BLCM was delisted on the 1st of June, 2023.
70 hedge funds and large institutions have $371M invested in Bellicum Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 27 increasing their positions, 19 reducing their positions, and 7 closing their positions.
180% more capital inflows, than outflows
Capital inflows: $28.5M | Capital outflows: $10.2M
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
42% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 19
4% more funds holding
Funds holding: 67 → 70 (+3)
3.55% more ownership
Funds ownership: 65.22% → 68.77% (+3.6%)
34% less call options, than puts
Call options by funds: $815K | Put options by funds: $1.24M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$18.1M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.13M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.44M |
| 4 |
BlackRock Institutional Trust
San Francisco,
California
|
+$1.13M |
| 5 |
BlackRock Fund Advisors
San Francisco,
California
|
+$1.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Foresite Capital Management III
Larkspur,
California
|
-$2.67M |
| 2 |
JP Morgan Chase
New York
|
-$2.09M |
| 3 |
QVT Financial
New York
|
-$2.05M |
| 4 |
Kennedy Capital Management
St Louis,
Missouri
|
-$1.1M |
| 5 |
Goldman Sachs
New York
|
-$838K |
BLCM Hedge Fund Activity: Q3 2016 in Review
70 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals (BLCM) for Q3 2016, worth a combined $371M — up 62% from $229M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new BLCM positions and 7 closed out — a net gain of 3 holders — while 27 added to existing stakes and 19 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $18.1M. The largest seller was Foresite Capital Management III, exiting entirely with an estimated $2.67M sold.
- 70 institutional investors held Bellicum Pharmaceuticals (BLCM) as of Q3 2016, up from 67 in Q2 2016.
- Funds reported $371M of Bellicum Pharmaceuticals stock for Q3 2016, up 62% quarter-over-quarter.
- 10 funds opened new Bellicum Pharmaceuticals positions in Q3 2016 and 7 closed out, a net change of +3 holders.
- The largest Bellicum Pharmaceuticals buyer in Q3 2016 was Fidelity Investments, an estimated $18.1M added.
- The largest Bellicum Pharmaceuticals seller in Q3 2016 was Foresite Capital Management III, an estimated $2.67M sold.
Based on aggregated 13F filings for Q3 2016.